ENTB, Entest Biomedical Inc., has been and currently is a strong stock. We have been following this stock for a while now and consistently see progression in the right direction. What ENTB is doing is focusing in on one specific area, a COPD cure, and earning revenue on things they find along the way. An example of this would be the newly discovered stem cell line they have claimed.

With the finding of the new stem cell line, ENTB can partner with existing companies and sell them usage rights. This means that ENTB can help fund their COPD endeavors and maintain a self-sufficient status. Translating this into the investor’s hands is a better PPS and more profit lines.

During our steady gain there have been profit takers along the way, which is to be expected; however, it has not affected the stock price negatively. The company principals are just as sound as the stock, as well, which makes for a win-win situation for shareholders.

Those investors in ENTB know what kind of gem ENTB is and it has not widely been exposed. The growth we have seen from this stock is nothing short of productive and should continue its upward path before it shoots straight up with news of a breakthrough in the COPD treatment.

It is not every day that investors find a stock that they can set aside and let mature. ENTB is one of those stocks and the potential to hit the all-time high is clearly within grasp. For those who would like to do due diligence on ENTB, visit their blog site located at http://www.entestbioblog.com and click on “live” to see webcasts that the company has previously done live. This will give you a good insight on the steps the company is taking to achieve their goals. They have recently started adding guests to their live webcasts to help clarify points in the process of creating the COPD treatment happen.

Reviewing past press releases and searching online will provide plenty of necessary information to understand why Entest Biomedical, Inc. is a solid investment. With COPD being the fourth leading cause of death in the United States, there is a huge potential for large sums of money to be made by the company and shareholders. A little patience with ENTB stands to go a very long way indeed. We would love to be in on the ground floor of a company that ultimately finds the cure for the 4th leading cause of death in the U.S. The thought of what an achievement such as that would have on the share price is mind-boggling!